Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2010

View Archived Issues

Safety and preliminary efficacy shown for SAM-531 in AD

Vertex scientists present new ATR kinase inhibitors

Carraguard protects against human papillomavirus infection

Cubist Pharma claims new antibacterial cyclic lipopeptides

Incyte discloses new histamine H4 receptor antagonists

Merck & Co. identifies new gamma-secretase modulators

Merck & Co. claims new GPR119 receptor agonists

Scientists identify SNPs implicated in heritability of human height and longevity

EGR2 gene SNPs are linked to susceptibility to systemic lupus erythematosus

Impact of LibiGel on cognitive function to be evaluated in menopausal women

FDA grants orphan drug status to Keryx's perifosine for neuroblastoma

Aastrom begins extension study of control patients from phase II IMPACT-DCM trial

Merck KGaA identifies new tyrosine kinase inhibitors

Mylan plans to acquire Bioniche Pharma

Decentralized procedure for European approval of pitavastatin reaches positive conclusion

R-Tech Ueno discloses phase II data on UF-021 in retinitis pigmentosa

Sanofi-aventis and Novalar submit OraVerse MAA in five European countries

International Stem Cell Institute launches stem cell therapy to treat symptoms of cerebral palsy

Cytos and A*STAR join to develop virus-like particle influenza vaccine

Invida to commercialize Amdipharm's products in Asia under new agreement

Biogen acquires rights to Amorfix's monoclonal antibodies for ALS

FDA committees vote to keep rosiglitazone on the market; Takeda defends pioglitazone

Merck KGaA acquires Millipore and launches EMD Millipore

FDA advisory committee votes against approval of Qnexa for obesity

TA Therapeutics' telomerase activator program consolidated into Geron

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...